Jonathan Anderman has bought CMPX on 2 days since Apr 2025
General Counsel at Compass Therapeutics, Inc.
SEC CIK 0002032625 · Filings on SEC.gov ↗
Jonathan Anderman's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
2 filings since Apr 2025, newest first
About Jonathan Anderman
Jonathan E. Anderman, JD, is Senior Vice President, General Counsel, and Corporate Secretary at Compass Therapeutics, Inc. (CMPX), a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics.( He joined the company in August 2021, overseeing legal, corporate governance, and compliance functions, and has recently engaged in insider trading, including purchasing 25,000 shares at $1.89 each and holding approximately 46,000 shares valued at $243,340 as of March 31, 2026.(
Anderman brings extensive experience in healthcare and life sciences law. Prior to Compass, he served as Global Commercial Counsel at Biogen, Inc. (2020-2021) and Assistant General Counsel at Intarcia Therapeutics, Inc. (2018), advising on corporate transactions, commercialization, and compliance.( Earlier, he was a healthcare attorney at Holland & Knight, representing clients on regulatory and transactional matters.( He earned his JD from Boston University School of Law and BA from The Pennsylvania State University.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.